These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11436153)

  • 21. A new method for detecting activated and neoplastic mesothelial cells in serous effusions.
    Donna A; Betta PG; Gagliardi F; Provana A
    IARC Sci Publ; 1980; (30):183-6. PubMed ID: 6165686
    [No Abstract]   [Full Text] [Related]  

  • 22. [Recognition of mesothelial cells in serous cavity fluid].
    Shiller-Volkova NN; Klimanova ZF
    Lab Delo; 1969; 10():612-6. PubMed ID: 4193059
    [No Abstract]   [Full Text] [Related]  

  • 23. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions.
    Metzgeroth G; Kuhn C; Schultheis B; Hehlmann R; Hastka J
    Cytopathology; 2008 Aug; 19(4):205-11. PubMed ID: 17573908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
    Ordóñez NG
    Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.
    Ordóñez NG
    Hum Pathol; 2007 Jan; 38(1):1-16. PubMed ID: 17056092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clear cell mesothelioma of the testis with deciduoid areas--a case report.
    Mishra A; Shet T
    Indian J Pathol Microbiol; 2004 Oct; 47(4):544-6. PubMed ID: 16295392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study.
    Markaki S; Protopapas A; Milingos S; Lazaris D; Antsaklis A; Michalas S
    Gynecol Oncol; 2005 Mar; 96(3):860-4. PubMed ID: 15721439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions.
    Zimmerman RL; Goonewardene S; Fogt F
    Mod Pathol; 2001 Aug; 14(8):748-51. PubMed ID: 11504833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. nm23 is expressed in reactive mesothelium and is not useful for detection of malignant cells in serous effusions.
    Zimmerman RL; Fogt F
    Oncol Rep; 2006 Jan; 15(1):85-8. PubMed ID: 16328038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Differential diagnosis of pleural effusions].
    Igonin VA; Dmitrashchenko AA; Akhiev MI; Fisun AIa; Beliakin SA
    Klin Med (Mosk); 2009; 87(7):56-9. PubMed ID: 19705795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular testing on serous effusions.
    Davidson B
    Diagn Cytopathol; 2021 May; 49(5):640-646. PubMed ID: 32023012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions.
    Davidson B; Dong HP; Holth A; Berner A; Risberg B
    Breast J; 2008; 14(5):476-82. PubMed ID: 18657145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors.
    Amin MB
    Mod Pathol; 2005 Feb; 18 Suppl 2():S131-45. PubMed ID: 15502808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
    Takeshima Y; Amatya VJ; Kushitani K; Inai K
    Am J Clin Pathol; 2008 Nov; 130(5):771-9. PubMed ID: 18854270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions.
    Doviner V; Maly B; Reinhartz T; Vlodavsky I; Sherman Y
    Cytopathology; 2007 Feb; 18(1):13-9. PubMed ID: 17250598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease.
    Liu CL; Hsieh WY; Wu CL; Kuo HT; Lu YT
    Respir Med; 2007 May; 101(5):903-9. PubMed ID: 17097866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications.
    Davidson B; Dong HP; Holth A; Berner A; Risberg B
    Diagn Cytopathol; 2007 Sep; 35(9):568-78. PubMed ID: 17703449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.